Form 4: Envoy Medical Director Mona Patel Boosts Stake with Significant Stock Purchase

Envoy Medical, Inc. Director Mona Chetan Patel reported the acquisition of 10,000 shares of Class A Common Stock, signaling increased insider confidence in the company.

Summary

• Envoy Medical, Inc. Director Mona Chetan Patel purchased 10,000 shares of the company's Class A Common Stock on June 6, 2025.
• The shares were acquired at a weighted average price of $1.46, with individual transaction prices ranging from $1.42 to $1.4981.
• Following this transaction, Ms. Patel directly holds 17,500 shares of Class A Common Stock.
• Ms. Patel also holds 25,000 stock options with an exercise price of $2.40, which expire on October 15, 2033.
• These options have a vesting schedule: 6,250 shares vest on October 15, 2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

Sentiment

Score: 8

Explanation: The direct purchase of company stock by a director is a strong positive signal, indicating confidence in the company's valuation and future, despite the limited scope of a Form 4 filing.

Positives

• A director's purchase of company stock indicates strong confidence in the company's future prospects and valuation.
• The acquisition of 10,000 shares by Director Mona Chetan Patel increases insider alignment with shareholder interests.

Negatives

• No negative information was disclosed in this Form 4 filing.

Risks

• No specific risks were detailed in this insider transaction report.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider's transaction.

Industry Context

This Form 4 filing, detailing an insider stock purchase, does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• This Form 4 filing, which reports an insider transaction, does not contain information that allows for a direct comparison to industry-specific financial benchmarks or project results.

Stakeholder Impact

• Shareholders may perceive the director's stock purchase as a positive indicator of the company's intrinsic value and future performance, potentially boosting investor confidence.

Next Steps

• The vesting of 6,250 stock options on October 15, 2024.
• The pro rata monthly vesting of the remaining 18,750 stock options over 36 consecutive months starting from October 15, 2024.

Key Dates

Recommendation

Keywords

Envoy Medical, COCH, Form 4, Insider Trading, Stock Purchase, Director, Mona Chetan Patel, Beneficial Ownership, Equity Acquisition, Stock Options